Bile acid is important for gastrointestinal absorption of nilotinib

Larson RA, Yin OQ, Hochhaus A, Saglio G, Clark RE, Nakamae H, Gallagher NJ, Demirhan E, Hughes TP, Kantarjian HM, le Coutre PD (2011) Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase. Eur J Clin Pharmacol. doi:10.1007/s00228-011-1200-7 van Erp NP, Gelderblom H, Guchelaar HJ (2009) Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev 35(8):692–706. doi:10.1016/j.ctrv.2009.08.004 Tanaka C, Yin OQ, Sethuraman V, Smith T, Wang X, Grouss K, Kantarjian H, Giles F, Ottmann OG, Galitz L, Schran H (2010) Clinical pharmacokinetics of the BCR-ABL tyrosine kinase inhibitor nilotinib. Clin Pharmacol Ther 87(2):197–203. doi:10.1038/clpt.2009.208 Takahashi N, Miura M, Niioka T, Sawada K (2011) Influence of H2-receptor antagonists and proton pump inhibitors on dasatinib pharmacokinetics in Japanese leukemia patients. Cancer Chemother Pharmacol. doi:10.1007/s00280-011-1797-3 Miura M, Takahashi N, Sawada K (2010) High-performance liquid chromatography with solid-phase extraction for the quantitative determination of nilotinib in human plasma. BMC 24(7):789–793. doi:10.1002/bmc.1364